In today's investment landscape, the healthcare sector stands out as a promising area for long-term investors. With aging populations, increasing healthcare expenditures, and ongoing groundbreaking innovations, the industry's future looks bright. Among the myriad of investment opportunities, two ASX healthcare shares have caught my attention due to their recent decline from historical highs. These shares, I believe, present an intriguing opportunity for investors seeking long-term growth and market-beating returns.
CSL Ltd: A Global Leader in Plasma Therapies
CSL Ltd, a biotech giant, has experienced a challenging period, which is reflected in its share price performance. However, I remain optimistic about the company's prospects. Its CSL Behring division continues to dominate the global plasma therapies market, catering to chronic and rare diseases that require sustained treatment. This recurring revenue stream, coupled with a robust pipeline of innovative products and a solid presence in vaccines and specialty pharmaceuticals, positions CSL well for future growth.
The recent share price weakness has made CSL more attractive from a valuation perspective. With multiples returning to historical lows and a positive long-term growth outlook, the risk-reward profile is now more favorable. Over the next 5 to 10 years, I anticipate CSL regaining momentum as its growth drivers take effect and execution improves, making it an attractive buy-and-hold investment.
ResMed Inc: Building an Ecosystem for Sleep Apnoea Treatment
ResMed operates in the sleep apnoea space, an area with significant global growth potential. Despite being underdiagnosed, sleep apnoea affects over 1 billion people worldwide, and increasing awareness and technological advancements are driving demand for ResMed's devices and software solutions. What sets ResMed apart is its holistic approach, combining hardware with cloud-based software and data insights to support patients and healthcare providers throughout the treatment journey. This integrated ecosystem strengthens ResMed's competitive position and sets it up for continued growth.
With the ResMed share price trading below previous highs, the long-term investment case looks compelling. The combination of structural demand and a strong market position provides a clear growth trajectory. As a result, I believe ResMed shares offer an attractive entry point for long-term investors.
Foolish Takeaway
Both CSL and ResMed are well-positioned to benefit from long-term demand and ongoing innovation in the healthcare sector. While their recent share price declines may be a cause for concern for existing shareholders, I view them as an opportunity for new investors. Over a 5 to 10 year timeframe, I expect these shares to deliver strong returns and outperform the market, making them an attractive addition to any long-term investment portfolio.
